|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Procainamide#Adult Indications and Dosage]] |
| {{Propafenone}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| RYTHMOL SR® is indicated to prolong the time to recurrence of symptomatic [[atrial fibrillation]] (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease.
| |
| | |
| Usage Considerations:
| |
| | |
| *The use of RYTHMOL SR in patients with permanent AF or in patients exclusively with atrial flutter or paroxysmal [[supraventricular tachycardia]] (PSVT) has not been evaluated. Do not use RYTHMOL SR to control ventricular rate during AF.
| |
| *Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended.
| |
| *The effect of propafenone on mortality has not been determined [see Boxed Warning].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RYTHMOL SR (PROPAFENONE HYDROCHLORIDE) CAPSULE, EXTENDED RELEASE [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bb1bc4a-a019-49c8-af81-be899822428f | publisher = | date = | accessdate = 13 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| [[Category:Antiarrhythmic agents]]
| |
| [[Category:Ketones]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Alcohols]]
| |
| [[Category:Amines]]
| |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |